Matinas BioPharma Files 8-K for Reg FD Disclosure on Jan 9, 2024

Ticker: MTNB · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1582554

Matinas Biopharma Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyMatinas Biopharma Holdings, Inc. (MTNB)
Form Type8-K
Filed DateJan 9, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, corporate-governance, disclosure

TL;DR

**Matinas BioPharma just dropped an 8-K for Reg FD, new info coming!**

AI Summary

Matinas BioPharma Holdings, Inc. filed an 8-K on January 9, 2024, primarily for Regulation FD Disclosure and to include financial statements and exhibits. This filing, under the Securities Exchange Act of 1934, indicates that the company is providing information that was previously non-public, likely to ensure fair and broad dissemination. For investors, this matters because it suggests Matinas BioPharma is making new, material information available, which could influence stock performance, though the specific content of that information is not detailed in this particular filing.

Why It Matters

This filing signals that Matinas BioPharma is releasing new, potentially market-moving information to the public, which could impact its stock price (MTNB) on the NYSE American.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing for Regulation FD disclosure, which generally aims to reduce information asymmetry and is not inherently risky.

Analyst Insight

A smart investor would monitor Matinas BioPharma's news releases and subsequent filings closely for the specific information disclosed under Regulation FD, as this filing itself only signals that new information has been or will be made public, without detailing its content.

Key Players & Entities

  • Matinas BioPharma Holdings, Inc. (company) — the registrant filing the 8-K
  • January 9, 2024 (date) — date of earliest event reported and filing date
  • NYSE American (company) — exchange where Matinas BioPharma's Common Stock (MTNB) is registered

FAQ

What is the primary purpose of Matinas BioPharma Holdings, Inc.'s 8-K filing on January 9, 2024?

The primary purpose of Matinas BioPharma Holdings, Inc.'s 8-K filing on January 9, 2024, is for Regulation FD Disclosure and to include Financial Statements and Exhibits, as indicated in the 'ITEM INFORMATION' section of the filing.

What is the trading symbol and exchange for Matinas BioPharma Holdings, Inc.'s Common Stock?

Matinas BioPharma Holdings, Inc.'s Common Stock trades under the symbol 'MTNB' on the NYSE American, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' table.

What is the business address and phone number of Matinas BioPharma Holdings, Inc.?

The business address for Matinas BioPharma Holdings, Inc. is 1545 Route 206 South, Suite 302, Bedminster, New Jersey, 07921, and their telephone number is (908) 484-8805, according to the filing's 'BUSINESS ADDRESS' section.

Under which Act is this 8-K filing made?

This 8-K filing is made pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, as specified at the top of the 'FORM 8-K' document.

What is Matinas BioPharma Holdings, Inc.'s Central Index Key (CIK) and state of incorporation?

Matinas BioPharma Holdings, Inc.'s Central Index Key (CIK) is 0001582554, and its state of incorporation is Delaware, as detailed in the 'FILER: COMPANY DATA' section.

Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-01-09 07:30:25

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MATINAS BIOPHARMA HOLDINGS, INC. Dated: January 9, 2024 By: /s/ Jerome D. Jabbour Name: Jerome D. Jabbour Title: Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.